High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Pietro Lampertico, Roberta D’Ambrosio et al.|Journal of Hepatology|2020Cited by 392
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, Jinlin Hou, José Luís Calleja et al.|Journal of Hepatology|2020Cited by 346
Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon TherapyPietro Lampertico, Massimo Colombo, E. Del Ninno et al.|Hepatology|2003Cited by 218
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D’Ambrosio, S. Fagiuoli, L. Pasulo et al.|Journal of Hepatology|2018Cited by 132
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Pietro Lampertico, Roberta D’Ambrosio et al.|Clinical Gastroenterology and Hepatology|2018Cited by 114